University of Southampton

Cancer Research Technology Limited

Bioinvent International Ab

Biovent International Ab

Mark Steven Cragg

Martin John Glennie

Björn Frendéus

Ingrid Teige

Ali Roghanian

Stephen Beers

Sean Lim

Peter David Johnson

Linda Mårtensson

Aymen Al-Shamkhani

Hak Tak Claude Chan

Jane Elizabeth Willoughby

Ruth Rosemary French

Aymen Al-shamkhani

Robert Oldham

Björn Frendeus

Bjoern Frendeus

Described is the use of a first antibody molecule that specifically binds FcγRIIb via its Fab region, but lacks Fc region or has reduced binding to Fcγ receptors via its Fc region, for use in combination with a second antibody molecule that specifically binds to a receptor present on an immune cell, wherein the immune cell is an immune cell that suppresses anti-cancer immunity, which second antibody molecule has an Fc region that binds to at least one activating Fcγ receptor, and wherein the binding of the second antibody molecule to the receptor on the immune cell causes depletion and/or deactivation of the immune cell in the treatment of an FcγRIIb-negative cancer in a patient, as well as pharmaceutical compositions and kits comprising these to antibody molecules, and methods of treating cancer using these two antibodies.

Combination and use of antibodies

Description of a composition comprising an antibody molecule and an agent for use in the treatment of refractory cancer and/or relapsed cancer, and of a method of treating refractory cancer and/or relapsed cancer comprising administering an antibody molecule and an agent. There are also described kits comprising the antibody molecule and agents.

Medicaments, uses and methods

The disclosure relates to a method of treatment or prevention of B-cell related disease in a subject comprising the administration of a binding molecule capable of binding to a B-cell and promoting killing of the B-cell; and an immunostimulatory agent arranged to stimulate effector lymphocytes, such as NK and/or T cells. Additionally, an anti-CD27 binding agent for use in a combination therapy with an anti-CD20 binding agent for the treatment or prevention of B-cell related disease in a subject. The disclosure also relates to a method of treatment or prevention of cancer in a subject comprising the administration of a cancer-cell-depleting binding agent capable of binding to the cancer cell and promoting killing of the cancer cell; and an immunostimulatory agent arranged to stimulate NK and/or T-cell activation. Additionally, an anti-CD27 binding agent for use in a combination therapy with a cancer-cell-depleting binding agent for the treatment or prevention of cancer in a subject.

Cancer and B-cell related disease therapy

The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.

Immunomodulatory antibodies

The invention provides a method of treating a patient having target cells that express Fc&#x3b3;RIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding Fc&#x3b3;RIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and Fc&#x3b3;RIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of Fc&#x3b3;RIIb.

Combined use of Fc&#x3b3;RIIb (CD32B) and CD20 specific antibodies

The invention provides a method of treating a patient having target cells that express FcyRIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding FcyRIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and FcyRIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of FcyRIIb.

Combined use of Fc gamma RIIb (CD32B) and CD20-specific antibodies

Growing community of inventors

Southampton, United Kingdom

Mark Steven Cragg